Vicplas International Ltd, listed on the SGX Mainboard, has announced a 14.9% increase in revenue for the first half of 2026, reaching S$62.4m. This growth was driven by higher sales in both its medical devices and pipe and pipe fittings segments. However, the company reported a loss after tax of S$3.4m, a significant decline from a profit of S$0.2m in the same period last year.
The medical devices segment, whilst showing signs of recovery with increased orders and new project commercialisations in Singapore, China, and Mexico, faced short-term constraints impacting its profitability. The Mexico plant, which began small-scale production, has been awarded new projects expected to boost future revenues. Despite these developments, the segment’s results were negatively affected by the costs associated with new investments in cleanrooms and machinery.
The pipes and pipe fittings segment benefited from robust construction activities in Singapore, particularly in public housing and civil engineering projects. However, the segment continues to face challenges from intensified competition and volatile raw material costs. The company plans to focus on green building materials and local manufacturing to enhance supply chain resilience.
CEO Walter Tarca noted the complex operating environment, citing geopolitical conflicts and supply chain disruptions as ongoing challenges. He emphasised the company’s commitment to prudent cost management and exploring new business opportunities to strengthen its foundation for long-term growth.
